Search: onr:"swepub:oai:lup.lub.lu.se:3efc46dd-bbc8-4a57-94ec-42a781949adf" >
Serum biomarkers fo...
-
Hambardzumyan, KarenKarolinska University Hospital
(author)
Serum biomarkers for prediction of response to methotrexate monotherapy in early rheumatoid arthritis : Results from the SWEFOT trial
- Article/chapterEnglish2019
Publisher, publication year, extent ...
-
2019-02-01
-
The Journal of Rheumatology,2019
-
9 s.
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:3efc46dd-bbc8-4a57-94ec-42a781949adf
-
https://lup.lub.lu.se/record/3efc46dd-bbc8-4a57-94ec-42a781949adfURI
-
https://doi.org/10.3899/jrheum.180537DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:141041599URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Objective. To investigate baseline levels of 12 serum biomarkers that constitute a multibiomarker disease activity test, as predictors of response to methotrexate (MTX) in patients with early rheumatoid arthritis (eRA). Methods. In 298 patients from the Swedish Pharmacotherapy (SWEFOT) clinical trial, baseline serum levels of 12 proteins were analyzed for association with disease activity based on the 28-joint count Disease Activity Score (DAS28) after 3 months of MTX monotherapy using uni-/multivariate logistic regression. Primary outcome was low disease activity (LDA; DAS28 ≤ 3.2). Results. Of 298 patients, 104 achieved LDA after 3 months on MTX. Four of the 12 biomarkers [C-reactive protein (CRP), leptin, tumor necrosis factor receptor I (TNF-RI), and vascular cell adhesion molecule 1 (VCAM-1)] significantly predicted LDA based on stepwise logistic regression analysis. Dichotomization of patients using receiver-operating characteristic curve analysis-based cutoffs for these biomarkers showed significantly higher proportions with LDA among patients with lower versus higher levels of CRP or leptin (40% vs 23%, p = 0.004, and 40% vs 25%, p = 0.011, respectively), as well as among those with higher versus lower levels of TNF-RI or VCAM-1 (43% vs 27%, p = 0.004, and 41% vs 25%, p = 0.004, respectively). Combined score based on these biomarkers, adjusted for known predictors of LDA (smoking, sex, and age), associated with decreased chance of LDA (adjusted OR 0.45, 95% CI 0.32–0.62). Conclusion. Low baseline levels of CRP and leptin, and high baseline levels of TNF-RI and VCAM-1 were associated with LDA after 3 months of MTX therapy in patients with eRA. Combination of these 4 biomarkers increased accuracy of prediction.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Bolce, Rebecca J.Lund University,Skåne University Hospital
(author)
-
Wallman, Johan K.Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-jnk
(author)
-
Van Vollenhoven, Ronald F.Karolinska Institutet,Karolinska Institute,Karolinska University Hospital
(author)
-
Saevarsdottir, SaedisKarolinska Institutet,Karolinska Institute
(author)
-
Karolinska University HospitalLund University
(creator_code:org_t)
Related titles
-
In:Journal of Rheumatology: The Journal of Rheumatology46:6, s. 555-5630315-162X1499-2752
Internet link
Find in a library
To the university's database